Grantham Mayo Van Otterloo & Co. LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 78.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 13,068 shares of the biopharmaceutical company's stock after selling 47,570 shares during the period. Grantham Mayo Van Otterloo & Co. LLC's holdings in Gilead Sciences were worth $1,207,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Nicolet Advisory Services LLC grew its holdings in shares of Gilead Sciences by 2.9% in the fourth quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company's stock worth $322,000 after acquiring an additional 100 shares during the period. Southland Equity Partners LLC boosted its position in Gilead Sciences by 3.6% in the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company's stock worth $289,000 after purchasing an additional 110 shares during the last quarter. Berkshire Bank grew its stake in shares of Gilead Sciences by 3.4% during the 4th quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company's stock valued at $314,000 after purchasing an additional 111 shares during the period. CFO4Life Group LLC increased its position in shares of Gilead Sciences by 2.7% during the 4th quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company's stock valued at $394,000 after purchasing an additional 112 shares during the last quarter. Finally, Howe & Rusling Inc. lifted its stake in shares of Gilead Sciences by 2.5% in the 4th quarter. Howe & Rusling Inc. now owns 4,704 shares of the biopharmaceutical company's stock worth $435,000 after purchasing an additional 115 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.
Insider Buying and Selling at Gilead Sciences
In related news, CFO Andrew D. Dickinson sold 142,180 shares of Gilead Sciences stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company's stock, valued at approximately $12,626,253.06. The trade was a 52.26 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 302,785 shares of company stock worth $30,503,250 over the last quarter. Insiders own 0.16% of the company's stock.
Analysts Set New Price Targets
Several brokerages recently issued reports on GILD. JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Wells Fargo & Company boosted their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. DZ Bank upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective for the company in a research note on Thursday, February 13th. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Finally, Bank of America raised their price objective on Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $105.12.
Check Out Our Latest Stock Report on Gilead Sciences
Gilead Sciences Price Performance
GILD stock traded up $2.98 during trading on Friday, hitting $104.38. 2,731,018 shares of the company's stock traded hands, compared to its average volume of 7,465,749. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96. The stock has a market capitalization of $129.96 billion, a price-to-earnings ratio of 280.72, a P/E/G ratio of 0.71 and a beta of 0.32. The business has a fifty day simple moving average of $108.23 and a 200 day simple moving average of $96.64. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.
Gilead Sciences Increases Dividend
The company also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 3.03%. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences's payout ratio is presently 854.05%.
Gilead Sciences Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
